Supriya Lifescience Reports Q2 FY27 Results Amid Margin Contraction
Supriya Lifescience Ltd 路 Press Release 路 07 Nov 2026, 12:47 am
Supriya Lifescience Reports Q2 FY27 Results Amid Margin Contraction Supriya Lifescience reported Q2 FY27 revenue of Rs 206.30 crore, up 3.2% YoY from Rs 199.83 crore. EBITDA dropped to Rs 45.40 crore from Rs 72.65 crore in Q2 FY26, with EBITDA margin compressing to 22.0% from 36.4%. PAT fell to Rs 29.25 crore from Rs 50.43 crore, reflecting higher input costs, Ambernath facility ramp-up expenses, and LATAM regulatory shifts. H1 FY27 revenue reached Rs 396.04 crore, up 14.8% YoY. The company launched two anaesthetic products and scheduled an EU audit for Nov'26.
Original exchange filing (PDF)
More announcements from Supriya Lifescience Ltd
- Earnings Call Transcript is enclosed herewith. 路 13 Nov 2026
- Outcome of the Results Earning Call for Quarter and Half year ended September 30, 2026 is enclosed herewith. 路 07 Nov 2026
- Investor Presentation is enclosed for the Results Earnings Call for quarter and half year ended September 30, 2026. 路 06 Nov 2026
- Change In Management - Appointment of Senior Management Personnel of the Company. 路 06 Nov 2026
- Please find enclosed. 路 06 Nov 2026
- Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 06 Nov 2026
- Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held .... 路 06 Nov 2026
- Enclosed herewith is the announcement under Regulation 30 of SEBI (LODR) Regulations, 2015. Kindly take the same on record. 路 03 Nov 2026
